Astrazeneca plc ADR (NASDAQ:AZN) has a beta value of 0.51 and has seen 0.64 million shares traded in the recent trading session. The company, currently valued at $203.05B, closed the recent trade at $65.49 per share which meant it lost -$0.37 on the day or -0.56% during that session. The AZN stock price is -16.9% off its 52-week high price of $76.56 and 7.67% above the 52-week low of $60.47. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.77 million shares traded. The 3-month trading volume is 6.24 million shares.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Sporting -0.56% in the red today, the stock has traded in the red over the last five days, when the AZN stock price touched $65.49 or saw a rise of 3.31%. Year-to-date, Astrazeneca plc ADR shares have moved -2.76%, while the 5-day performance has seen it change -3.09%. Over the past 30 days, the shares of Astrazeneca plc ADR (NASDAQ:AZN) have changed 0.69%. Short interest in the company has seen 9.26 million shares shorted with days to cover at 1.13.
Astrazeneca plc ADR (AZN) estimates and forecasts
Figures show that Astrazeneca plc ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -1.77% over the past 6 months, with this year growth rate of 12.12%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 30.20% and 25.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 10.90%.
4 analysts offering their estimates for the company have set an average revenue estimate of $11.98 billion for the current quarter. 3 have an estimated revenue figure of $12.46 billion for the next quarter concluding in Jun 2024. Year-ago sales stood $10.55 billion and $10.96 billion respectively for this quarter and the next, and analysts expect sales will grow by 13.50% for the current quarter and 13.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 17.72% over the past 5 years. Earnings growth for 2024 is a modest 12.38% while over the next 5 years, the company’s earnings are expected to increase by 12.80%.
AZN Dividends
Astrazeneca plc ADR is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.45 at a share yield of 2.21%. The company’s dividend yield has gone up over the past 12 months.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Insiders own 0.00% of the company shares, while shares held by institutions stand at 16.80% with a share float percentage of 16.80%. Investors are also buoyed by the number of investors in a company, with Astrazeneca plc ADR having a total of 1,344 institutions that hold shares in the company. The top two institutional holders are Price (T.Rowe) Associates Inc with over 52.27 million shares worth more than $3.42 billion. As of Dec 30, 2023, Price (T.Rowe) Associates Inc held 1.99% of shares outstanding.
The other major institutional holder is Wellington Management Group, LLP, with the holding of over 49.44 million shares as of Dec 30, 2023. The firm’s total holdings are worth over $3.24 billion and represent 1.88% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard/Primecap Fund and Washington Mutual Investors Fund. As of Dec 30, 2023, the former fund manager holds about 0.98% shares in the company for having 25.73 million shares of worth $1.68 billion while later fund manager owns 21.73 million shares of worth $1.42 billion as of Dec 30, 2023, which makes it owner of about 0.83% of company’s outstanding stock.
